NEW YORK — The responsibility for diagnosing and treating chronic spontaneous urticaria (CSU), for which there is a newly approved drug, should be in the hands of dermatologists who have the skills, ...

Dupilumab shows significant efficacy in reducing itch and hives in CSU patients unresponsive to antihistamines. The CUPID A and CUPID C trials reported a two-thirds reduction in itch and urticaria ...

"[Physicians] should advise patients that [CSU] is not a life-threatening disease, often occurs due to autoimmunity, and typically resolves within several years [and patients] should also be referred ...

"By capturing key PROs, these tools underscore the importance of focusing on patient experiences to optimize management strategies for CSU, thereby enhancing patient care and outcomes… The traditional ...

Data on new treatments for chronic spontaneous urticaria (CSU) show significant symptom reduction very early during treatment. There are multiple new drugs and mechanisms that are very promising to ...

During the Conversations in Dermatology 2025 conference, expert physicians who manage pruritic conditions will discuss challenging cases and the latest developments for the treatment of chronic ...

An update to the guidelines for urticaria management was published, involving collaboration from various international ...